India Artificial Intelligence (AI) in Diagnostics Market Analysis Sample Report

1. A sample report on India Artificial Intelligence (AI) in Diagnostics Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com

2. This report presents a strategic analysis of the India Artificial Intelligence (AI) in Diagnostics Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, types of clinical diagnostics, point-of-care testing, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the India Artificial Intelligence (AI) in Diagnostics Market, and offers unmatched value, accuracy, and expert insights

3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

4. Table of Content CONTENT PG. NO. 12-25 1. Artificial Intelligence (AI) in Diagnostics Overview 1.1. Overview 1.2. India Overview 1.3. Economic Overview: India 1.4. Artificial Intelligence (AI) in Diagnostics Market in India 1.5. Digital Health Market in India 1.6. Healthcare Scenario in India 1.7. Health Insurance Coverage: India 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 26-30 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1. By Component Outlook 2.2.2. By Diagnosis Outlook 31-35 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. India Artificial Intelligence (AI) in Diagnostics Market Driver 1 3.1.2. India Artificial Intelligence (AI) in Diagnostics Market Driver 2 3.1.3. India Artificial Intelligence (AI) in Diagnostics Market Driver 3 3.2. Market Restraints 3.2.1. India Artificial Intelligence (AI) in Diagnostics Market Restraint 1 3.2.2. India Artificial Intelligence (AI) in Diagnostics Market Restraint 2 5 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

6. Table of Content CONTENT PG. NO. 3.2.3. India Artificial Intelligence (AI) in Diagnostics Market Restraint 3 36-46 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. Qure.ai 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 4.2.2. Niramai 4.2.2.1. Overview 6 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

7. Table of Content CONTENT PG. NO. 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Predible Health 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 4.2.4. OncoStem Diagnostics 4.2.4.1. Overview 7 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

8. Table of Content CONTENT PG. NO. 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. Eyestem Research 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 4.2.6. Netra.AI 4.2.6.1. Overview 8 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

9. Table of Content CONTENT PG. NO. 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. SigTuple 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 4.2.8. OncoDiscover 4.2.8.1. Overview 9 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

10. Table of Content CONTENT PG. NO. 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. Aindra Systems 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 4.2.10. Forus Health 4.2.10.1. Overview 10 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

11. Table of Content CONTENT PG. NO. 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 47-54 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 5.4 Reimbursement Process – Medicare 5.5 Reimbursement Process - Medicaid 55-77 6. Methodology & Scope 11 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

12. India Artificial Intelligence (AI) in Diagnostics Market Analysis 1. Artificial Intelligence (AI) in Diagnostics Overview

13. 1.1 Statistics at a Glance: Global Utilization of Artificial Intelligence (AI) in Diagnostics Global scenario of Artificial Intelligence (AI) in Diagnostics Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ $11 Mn Was the worth of Artificial Intelligence in healthcare market in 2021 $188 Mn Is the forecasted worth of Artificial Intelligence in healthcare market in 2030 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 37.5% Is the expected CAGR of Artificial Intelligence market in Healthcare from 2023 to 2030 1 in 5 Healthcare organizations worldwide in 2021 were in early-stage initiatives of using artificial intelligence in their organizations In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 47.6% Was the share of North America in 2022, highest on the global level Artificial Intelligence (AI) market in healthcare Illustrative Illustrative 13 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

14. 1.1 Statistics at a Glance: Global Utilization of Artificial Intelligence (AI) in Diagnostics (continued) Europe ~Revenue to reach $xx Bn by 2027 North America ~ Market Size of $xx Bn Asia -xx% CAGR Africa Egypt Market ~$xx Mn Market ~Market Size of $xx Bn Illustrative Illustrative 14 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

15. 1.2 India Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 1.4 Bn Was the population of India, in 2022 $2.7 Tn Is the Gross Domestic Product (GDP) in India in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 28.4 years Was the median age in India, in 2022 $84 Bn Was the amount of national health expenditures of India in 2021 Illustrative Illustrative 15 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

16. 1.3 Economic Overview: India Population of India, (2020-2030) GDP of India, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

17. 1.4 Statistics at a Glance: Scenario of Artificial Intelligence (AI) in Diagnostics in India Artificial Intelligence (AI) in Diagnostics in India 57% Indians felt that doctors in the country will regularly use artificial intelligence to decide on treatment for their patients $150 million Is the amount invested in AI start-ups in India since 2012 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in India ▪ Triaging, detection and diagnostics are the high focus and high impact areas for AI in healthcare in India 464 Is the number of AI in Healthcare startups in India in 2023 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ National Health Stack & National Digital Health Blueprint are the recent documents to create a national digital health infrastructure Illustrative Illustrative 17 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

18. 1.5 Digital Health in India India Digital Health Market Forecast, 2022-2030 (in $Bn) xx xx xx xx xx xx xx xx xx 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Digital Health market in India, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 18 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

19. 1.6 Healthcare Scenario in India Artificial Intelligence (AI) in Diagnostics Drug Development Process: The process of developing a Artificial Intelligence (AI) in Diagnostics drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the Artificial Intelligence (AI) in Diagnostics drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating Artificial Intelligence (AI) in Diagnostics Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the India market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 19 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

20. 1.6 Healthcare Scenario: Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 20 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

21. 1.7 Health Insurance Coverage: India % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 21 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

22. 1.8 Budget of India Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% oftotal NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 22 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

23. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 23 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

24. 1.9 Mergers and Acquisitions (continued) Latest Deals In India Amount / Duration Company Name Type Year Key Pointers Diagnostic chain Metropolis Healthcare will acquire Dr Ganesan's Hitech Diagnostic Centre in a cash and stock combination deal, to strengthen its leadership position in southern India ▪ Acquisition $70.3 Mn Jan 2021 By the acquisition, Metropolis will get an access to 31 laboratories, including three NABL- and ICMR-accredited laboratories and 68 collection centers of Hitech ▪ HORIBA, SigTuple Partnership to accelerate adoption of SigTuple’s AI100 across the Indian subcontinent ▪ Partnership - Aug 2022 SigTuple leverages AI & robotics, to automate the error-prone and inefficient manual microscopic review of samples in laboratories ▪ 24 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

25. 1.9 Mergers and Acquisitions (continued) Latest Deals In India Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 25 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

26. India Artificial Intelligence (AI) in Diagnostics Market Analysis 2. Market Size and Forecasting

27. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption India Artificial Intelligence (AI) in Diagnostics Market Forecast, 2022- 2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Malaysia Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ % of India Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Malaysia Market Size (Bn $) 61 74 84 87 91 95 99 106 27 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

28. 2.2 Snapshot of Artificial Intelligence (AI) in Diagnostics Market Segmentation Component Outlook Diagnosis Outlook Software Cardiology Hardware Oncology Services Pathology Radiology Chest and Lung Neurology In this section you will get an understanding of the segmentations which will cover the India Artificial Intelligence (AI) in Diagnostics Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 28 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

29. 2.2.1 Market Segmentation: By Component Outlook Services market in India is a significant component of the overall Artificial Intelligence (AI) in Diagnostics treatment market ▪ India Artificial Intelligence (AI) in Diagnostics Market Share, By Component Outlook (2022) It has the maximum market share in India Artificial Intelligence (AI) in Diagnostics market with approximately xx% ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Software Services In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ Hardware 29 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

30. 2.2.3 Market Segmentation: By Diagnosis Outlook India Artificial Intelligence (AI) in Diagnostics Market Share, By Diagnosis Outlook (2022) Hospitals have the maximum market share in India Artificial Intelligence (AI) in Diagnostics market with approximately xx% ▪ Neurology Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Chest and Lung Cardiology In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Radiology Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Pathology Oncology Illustrative Illustrative 30 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

31. India Artificial Intelligence (AI) in Diagnostics Market Analysis 3. Market Dynamics

32. 3.1 Market growth drivers 3.1.1 Incidence of Artificial Intelligence (AI) in Diagnostics is increasing in India Utilization of Artificial Intelligence (AI) in Diagnostics in India Incidence of Artificial Intelligence (AI) in Diagnostics is increasing in India, with more than 1.8 Mn new Artificial Intelligence (AI) in Diagnostics cases expected to be diagnosed in 2023 ▪ This is driving the demand for Artificial Intelligence (AI) in Diagnostics treatments and creating opportunities for growth in the Artificial Intelligence (AI) in Diagnostics market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 32 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

33. 3.1 Market growth drivers (continued) 3.1.2 Death rate from cancer in India has declined by 31% from 1992 to 2022, largely due to advances in technology and treatment options Top countries that are leveraging technology in their fight against cancer India has a long history of investing in Artificial Intelligence (AI) in Diagnostics research and treatment, and as a result, has become a world leader in the field ▪ Norway IT has a robust healthcare infrastructure, including world- renowned research institutions, hospitals, and clinics, that are dedicated to Artificial Intelligence (AI) in Diagnostics treatment and research ▪ Austria Denmark Belgium Spain Italy Netherlands One of the key factors that has allowed India to stay ahead in the field of Artificial Intelligence (AI) in Diagnostics research and treatment is the high level of investment in Artificial Intelligence (AI) in Diagnostics-related research ▪ Sweden Singapore Switzerland Israel Australia In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Canada France United Kingdom Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ China South Korea Germany Japan United States Illustrative Illustrative 33 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

34. 3.1 Market growth drivers (continued) 3.1.3 In 2021, the cancer Institute (NCI) received $6.4 Bn in funding from India federal government to support cancer research and training programs Fundings from government and other organizations India government provides significant support and funding for cancer research and treatment, which is driving innovation and growth in the Artificial Intelligence (AI) in Diagnostics market ▪ Source Year Fund ($) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ National Artificial Intelligence (AI) in Diagnostics Institute (NCI) 2021 $ 6.4 Bn In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Centers for Disease Control and Prevention (CDC) 2021 $ 501 Mn Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ American Artificial Intelligence (AI) in Diagnostics Society (ACS) 2020 $ 150 Mn Susan G. Komen 2020 $ 98 Mn Illustrative Illustrative 34 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

35. 3.2 Market restraints 3.2.1 In 2020, the average cost of a new cancer drug was over $150,000 per year 3.2.2 Average cost of developing a new cancer drug that is ultimately approved by the FDA is over $2.6 Bn 3.2.3 Demand for cancer care is expected to increase by 42% by 2025, while the supply of oncologists is only expected to increase by 28% Cancer treatments can be very expensive and can lead to financial burden for patients and healthcare systems Cost of cancer treatment varies depending on the type of cancer, stage of cancer, and treatment options Some common cancer treatments, such as chemotherapy and radiation therapy, can cost tens of thousands of dollars Regulatory requirements for cancer treatments can be very stringent, which can slow down the approval process and limit access to new treatments Regulatory bodies, such as India Food and Drug Administration (FDA), require extensive clinical trials and safety data before approving new cancer This can be a lengthy and costly process, which can delay the availability of new treatments for patients There is a shortage of oncologists in India, which can limit access to cancer treatments and create barriers to growth in the cancer market Oncologists are physicians who specialize in the diagnosis and treatment of cancer With the aging population and the increasing incidence of cancer, there is a growing demand for oncologists However, the supply of oncologists is not keeping pace with the demand ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 35 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

36. India Artificial Intelligence (AI) in Diagnostics Market Analysis 4. Competitive Landscape

37. 4.1 Major Market Share Revenue of Major players in India Artificial Intelligence (AI) in Diagnostics Market ($ Mn) India Artificial Intelligence (AI) in Diagnostics market is a highly competitive space, with many companies developing and marketing Artificial Intelligence (AI) in Diagnostics treatments ▪ Other Some of the top companies in India Artificial Intelligence (AI) in Diagnostics market based on revenue and market share include ▪ Qure.ai is a Swiss multinational healthcare company that develops and markets Artificial Intelligence (AI) in Diagnostics treatments, including targeted therapies and immunotherapies ▪ In 2020, Qure.ai's oncology sales were approximately $24 Bn, making it one of the largest players in India Artificial Intelligence (AI) in Diagnostics market ▪ XX Illustrative Illustrative 37 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

38. 4.2 Key Company Profile Key Note: 1 Qure.ai Here is the list of top 10 companies which will cover in the final report ▪ 2 Niramai Each company will have slides for ▪ 3 Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Predible Health o o 4 OncoStem Diagnostics o o 5 Eyestem Research o 6 o Netra.AI o 7 SigTuple o 8 OncoDiscover ▪ 9 Aindra Systems ▪ 10 Forus Health 38 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

39. 4.2.1 Qure.ai Care Areas Founded in: 2016 ▪ Provider of an AI-based decision support tool for diagnostic images ▪ Its radiology solution can diagnose disease from CT Scans, MRIs, and X-rays as well as outline and quantify regions of interest such as tumors or lung disease patterns ➢ Lung Cancer HQ: Maharashtra, India Type: Private ➢ Tuberculosis ▪ It offers a digital pathology solution that can distinguish malignant from benign biopsies, and grade a variety of tumor types Revenue: $3.6 Mn ➢ Heart Failure ▪ Present in more than 70 countries Website: www.qure.ai. ➢ Neurocritical Care Services offered Other information Products Indications Qure AI raised $40 Mn / Series C from HealthQuad and 3 other investors in March 2022 to expand its presence in US and Europe qXR AI for Chest X-rays qER AI for Head CTs qCT-Lung AI for Lung Nodules Qure.ai has become the first AI health technology company to have received endorsement from The College of Radiographers (CoR) for conducting the Super User Training qVH Beta AI for Ultrasound qMSK AI for Musculoskeletal X-rays 39 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

40. 4.2.1 Qure.ai (continued) Partnerships Ecosystem Major Investors Major Partnerships ▪ Qure.ai has secured $40 million in a funding round led by Novo Holdings and HealthQuad ▪ The three organisations will collaborate to establish a framework for early diagnosis of lung cancer ▪ HealthQuad claims to be India’s leading digital health focused venture capital fund with assets under management of $200 Mn across two funds ▪ AstraZeneca has been partnering with Qure.ai through the A.Catalyst Network ▪ Qure.ai brings qXR, its deep-learning AI technology software, to Fujifilm's portable X-ray FDR Xair system, enabling the device to analyse radiographs ▪ Qure.ai has secured $4.27 Mn from SBRI Healthcare, in partnership with the NHS cancer programme and NHS Accelerated Access Collaborative ▪ Fujifilm and Qure’s technology will deliver a support tool to assist the care providers for accurate diagnosis faster 40 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

41. 4.2.1 Qure.ai (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers The collaboration between Qure.ai and Nuance helps make cutting-edge imaging AI easily integrated and accessible to different stakeholders in the US healthcare system ▪ Collaboration - April 2023 The SAMRIDH Healthcare Blended Financing Facility, supported by the U.S. Agency for International Development (USAID) and implemented by IPE Global, has committed to Qure.ai to scale Artificial Intelligence (AI)-enabled chest X-ray screening software, qXR, in 50 sites across more than 15 Indian states ▪ Investment $ 329,000 April 2022 41 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

42. 4.2.1 Qure.ai (continued) Revenues ($Bn), 2020-2030 According to Qure.ai's 2020 financial report, the company had revenue of $3.6 Mn in 2022 ▪ Qure.ai is a Venture Capital-Backed company 70.9 ▪ 70.3 63.3 Revenue generated by Qure.ai in 2022 reflects the company's continued growth and success in the healthcare industry ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 1 2 3 4 Illustrative Illustrative 42 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

43. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Artificial Intelligence (AI) in Diagnostics Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 43 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

44. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 44 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

45. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 45 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

46. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 46 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

47. India Artificial Intelligence (AI) in Diagnostics Market Analysis 5. Reimbursement Scenario

48. 5.1 Reimbursement Regulation Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Americans The reimbursement scenario in the India Artificial Intelligence (AI) in Diagnostics Market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Medicare: o ▪ Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Medicare covers many Artificial Intelligence (AI) in Diagnostics treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Medicaid: o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for Artificial Intelligence (AI) in Diagnostics treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for Artificial Intelligence (AI) in Diagnostics treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% Employer-Sponsored 49% ▪ Health Insurance Coverage, 2022 Illustrative Illustrative 48 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

49. 5.1 Reimbursement Regulation (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to Artificial Intelligence (AI) in Diagnostics treatments by requiring insurers to cover certain preventive services, including Artificial Intelligence (AI) in Diagnostics screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as Artificial Intelligence (AI) in Diagnostics Reimbursement for New Treatments: Reimbursement for new Artificial Intelligence (AI) in Diagnostics treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 49 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential

50. 5.1 Reimbursement Regulation (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid  Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities  Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in the India healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 50 A Sample Report on India Artificial Intelligence (AI) in Diagnostics Market Analysis I Confidential